Aigen Investment Management’s Travere Therapeutics TVTX Stock Holding History

Aigen Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,183	Closed	-$427K	–	787
2025 Q4	$427K	Buy	+11,183	New	+$364K	0.1%	272
2025 Q3	–	Sell	-16,789	Closed	-$248K	–	1096
2025 Q2	$248K	Buy	+16,789	New	+$278K	0.03%	588
2025 Q1	–	Sell	-19,072	Closed	-$332K	–	1040
2024 Q4	$332K	Buy	19,072 +6,892	+57%	+$122K	0.06%	450
2024 Q3	$170K	Buy	+12,180	New	+$127K	0.03%	613
2020 Q3	–	Sell	-9,992	Closed	-$204K	–	1111
2020 Q2	$204K	Sell	9,992 -20,053	-67%	-$319K	0.03%	709
2020 Q1	$438K	Sell	30,045 -14,194	-32%	-$214K	0.06%	459
2019 Q4	$628K	Buy	+44,239	New	+$565K	0.1%	278

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aigen Investment Management's TVTX Position: Q1 2026 in Review

Aigen Investment Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 11,183 shares — an estimated $427K sold.

Aigen Investment Management first reported a position in TVTX in Q4 2019 and held it in 7 quarters. The position peaked at $628K in Q4 2019. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Aigen Investment Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Aigen Investment Management sold 11,183 Travere Therapeutics shares in Q1 2026, an estimated $427K.
Aigen Investment Management first reported a position in Travere Therapeutics in Q4 2019 and held it in 7 quarters.
Aigen Investment Management's Travere Therapeutics position peaked at $628K in Q4 2019.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.